Rituximab
Drug375 mg/m2 D1
NCT Number: NCT00553943
The purpose of this study is to measure the rate of complete response (CR and UCR) at the end of a course of immuno-chemotherapy:
* before cerebral radiotherapy for PCL * after the course of immuno-chemotherapy for aggressive lymphomas with neuromeningeal involvement Toxicity of the protocol Overall survival Survival without relapse Long-term incidence of neurocognitive toxicity
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
ZNA Stuivenberg, Antwerp, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SEVERE DISTURBANCE OF HEART RHYTHM VENTRICULAR EJECTION FRACTION BELOW 50% HISTORY OF RECENT MYOCARDIAL INFARCTION
375 mg/m2 D1
50 mg D3
Time frame: End of treatment - 5 months
Time frame: End of study - 5 years
Lymphoma Study Association
Other
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05784415
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03744676
Disease Attributes, Hemic and Lymphatic Diseases
Los Angeles, California, United States
View Trial DetailsNCT03484702
Disease Attributes, Hemic and Lymphatic Diseases
Vienna, Austria
View Trial DetailsNCT03682796
Hemic and Lymphatic Diseases, Immune System Diseases
Gilbert, Arizona, United States
View Trial Details